Freeze-dried preparation containing high-purity PTH and method for producing same
10683335 ยท 2020-06-16
Assignee
Inventors
Cpc classification
A61K38/29
HUMAN NECESSITIES
A61K9/19
HUMAN NECESSITIES
G01N30/7233
PHYSICS
B65B63/08
PERFORMING OPERATIONS; TRANSPORTING
B65B55/12
PERFORMING OPERATIONS; TRANSPORTING
C07K14/635
CHEMISTRY; METALLURGY
A61P5/20
HUMAN NECESSITIES
International classification
B65B63/08
PERFORMING OPERATIONS; TRANSPORTING
B65B55/12
PERFORMING OPERATIONS; TRANSPORTING
A61K9/19
HUMAN NECESSITIES
G01N30/88
PHYSICS
F26B5/06
MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
C07K14/635
CHEMISTRY; METALLURGY
Abstract
Provided herein are freeze-dried preparations comprising a high-purity parathyroid hormone (PTH) peptide and one or more PTH analogs, and methods for the production thereof. Also provided is a test method for detecting PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like.
Claims
1. A method for producing a freeze-dried preparation containing human parathyroid hormone (PTH) (1-34), wherein the method is conducted in a pharmaceutical production facility, the method comprising: (a) preparing a solution comprising the human PTH (1-34); (b) loading the solution comprising the human PTH (1-34) into a freeze-drying apparatus; (c) producing a freeze-dried preparation comprising the human PTH (1-34) from the solution; and (d) controlling contact of the human PTH (1-34) with ozone in the air in a Grade A zone of the facility at least during (b) to produce the freeze-dried preparation comprising human PTH (1-34) in which (i) a ratio of an amount of any one human PTH (1-34) analog to the sum of the total amount of human PTH (1-34) and the total amount of human PTH (1-34) analogs in the freeze-dried preparation is 1.0% or less, and (ii) a ratio of the total amount of the human PTH (1-34) analogs to the sum of the total amount of human PTH (1-34) and the total amount of human PTH (1-34) analogs in the freeze-dried preparation is 5.0% or less; wherein the ozone in the air is present in an amount of from 0.02-0.1 ppm.
2. The method of claim 1, wherein the air comprises formaldehyde.
3. The method of claim 1, wherein the freeze-dried preparation is sterile.
4. The method of claim 1, wherein the human PTH analogs are selected from one or more of the group consisting of: a) analog 1 comprising an oxide of the human PTH (1-34) having a molecular weight 64 Daltons (Da) greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 1 produces digestion products corresponding to fragments (1-a) to (1-c), wherein (1-a) comprises the amino acid sequence Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys (SEQ ID NO: 1) having a molecular weight of about 1472 Da, (1-b) comprises the amino acid sequence His-Leu-Asn-Ser-Met-Glu-Arg (SEQ ID NO: 2) having a molecular weight of about 902 Da, and (1-c) comprises the amino acid sequence Val-Glu-Trp-Leu-Arg (SEQ ID NO: 3) having a molecular weight of about 706 Da; b) analog 2 comprising an oxide of the human PTH (1-34) having a molecular weight 36 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 2 produces digestion products corresponding to the fragments (1-a) to (1-c); c) analog 3 comprising an oxide of the human PTH (1-34) having a molecular weight 32 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 3 produces digestion products corresponding to the fragments (1-a) and (1-b); d) analog 4 comprising an oxide of the human PTH (1-34) having a molecular weight 48 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 4 produces digestion products corresponding to the fragments (1-a) and (1-c); e) analog 5 comprising an oxide of the human PTH (1-34) having a molecular weight 48 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 5 produces digestion products corresponding to the fragments (1-b) and (1-c); f) analog 6 comprising an oxide of the human PTH (1-34) having a molecular weight 20 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 6 produces digestion products corresponding to the fragments (1-b) and (1-c); g) analog 9 comprising an oxide of the human PTH (1-34) having a molecular weight 32 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 9 produces a digestion product corresponding to the fragment (1-c); h) analog 10 comprising an oxide of the human PTH (1-34) having a molecular weight 16 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 10 produces a digestion product corresponding to a fragment (1-d) comprises the amino acid sequence of SEQ ID NO: 3 and having a molecular weight of about 718 Da; i) analog 11 comprising an oxide of the human PTH (1-34) having a molecular weight 4 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 11 produces a digestion product corresponding to the fragment (1-c); j) analog 7 comprising an oxide of the human PTH (1-34) having a molecular weight 16 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 7 produces a digestion product corresponding to the fragment (1-a); and k) analog 8 comprising an oxide of the human PTH (1-34) having a molecular weight 16 Da greater than the molecular weight of the human PTH (1-34), wherein a trypsin digestion of the analog 7 produces a digestion product corresponding to the fragment (1-b).
5. The method of claim 1, wherein the human PTH analogs are selected from one or more of the group consisting of: a) analog 1 an oxide of the human PTH (1-34) in which residues corresponding to position 8 and position 18 methionine of the human PTH (1-34) are methionine sulfoxide residues and residue corresponding to a position 23 tryptophan is a residue of formula (a); b) analog 2 an oxide of the human PTH (1-34) in which the residues corresponding to the position 8 and position 18 methionine of the human PTH (1-34) are methionine sulfoxide residues and the residue corresponding to the position 23 tryptophan is a residue of formula (b); c) analog 3 an oxide of the human PTH (1-34) in which the residues corresponding to the position 8 and position 18 methionine of the human PTH (1-34) are methionine sulfoxide residues; d) analog 4 an oxide of the human PTH (1-34) in which the residue corresponding to the position 8 methionine of the human PTH (1-34) is a methionine sulfoxide residue and the residue corresponding to the position 23 tryptophan is the residue of formula (a); e) analog 5 an oxide of the human PTH (1-34) in which the residue corresponding to the position 18 methionine of the human PTH (1-34) is a methionine sulfoxide residue and the residue corresponding to the position 23 tryptophan is the residue of formula (a); f) analog 6 an oxide of the human PTH (1-34) in which the residue corresponding to the position 18 methionine of the human PTH (1-34) is a methionine sulfoxide residue and the residue corresponding to the position 23 tryptophan is the residue of formula (b); g) analog 9 an oxide of the human PTH (1-34) in which the residue corresponding to the position 23 tryptophan of the human PTH (1-34) is the residue of formula (a); h) analog 10 an oxide of the human PTH (1-34) in which the residue corresponding to the position 23 tryptophan of the human PTH (1-34) is a tryptophan monoxide residue of formula (c-1) or (c-2) below ##STR00007## i) analog 11 an oxide of the human PTH (1-34) in which the residue corresponding to the position 23 tryptophan of the human PTH (1-34) is the residue of formula (b); j) analog 7 an oxide of the human PTH (1-34) in which the residue corresponding to the position 8 methionine of the human PTH (1-34) is a methionine sulfoxide residue; and k) analog 8 an oxide of the human PTH (1-34) in which the residue corresponding to the position 18 methionine of the human PTH (1-34) is a methionine sulfoxide residue, wherein formula (a) is ##STR00008## and formula (b) is ##STR00009##
6. The method of claim 1, wherein (a) comprises dispensing the solution into one or more containers.
7. The method of claim 1, wherein the loading at (b) is carried out for a period of time of three or more hours.
8. The method of claim 6, wherein the containers are purged with an inert gas in advance of dispensing the solution or the freeze-drying apparatus is purged with an inert gas when loading the containers.
9. The method of claim 6, wherein the containers are glass vials.
10. The method of claim 1, wherein the freeze-drying apparatus comprises a freeze-drying chamber having an easily openable and closable sub-door provided in an opening created in a small door unit configured to be opened when the containers are loaded into or are unloaded from the chamber, and an inflow of the air within the pharmaceutical production facility into the freeze-drying apparatus is controlled by a process comprising opening the sub-door only during the loading and quickly closing the sub-door after the loading.
11. The method of claim 1, wherein the freeze-drying apparatus comprises a freeze-drying chamber having an opening created in a small door unit configured to be opened when the containers are loaded into or are unloaded from the chamber, and an inflow of air within the pharmaceutical production facility into the freeze-drying apparatus is controlled by a process comprising directing air flow within the pharmaceutical production facility away from the opening to the inside of the chamber by means of an airflow-adjusting cover configured to alter the air flow away from the opening of the chamber.
12. The method of claim 1, wherein the ratio of the amount of any one human PTH (1-34) analog to the sum of the total amount of human PTH (1-34) and the total amount of human PTH (1-34) analogs in the freeze-dried preparation is 0.6% or less.
13. The method of claim 1, wherein the ratio of the total amount of the human PT (1-34) analogs to the sum of the total amount of human PTH (1-34) and the total amount of human PTH (1-34) analogs in the freeze-dried preparation is 3.0% or less.
14. The method of claim 7, wherein the amount of the analog 1 in the preparation is 0.04% or less, the amount of the analog 3 and the analog 4 in the preparation is 0.11% or less, the amount of the analog 5 in the preparation is 0.26% or less; the amount of the analog 7 in the preparation is 0.33% or less; the amount of the analog 8 in the preparation is from 0.21-1.00%; and the amount of the analog 9 in the preparation is 0.68% or less.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18) The present invention shall now be described in further detail.
(19) (1) PTH Peptide
(20) The term PTH peptide in the present invention is used as a collective term for natural PTH and substances of equivalent physiologic activity. The physiologic activity of PTH is characterized as acting to raise the serum calcium. Preferred PTH peptides encompass natural PTH and partial peptides thereof, which may be peptides having a molecular weight of from about 4000 to 10,000. However, PTH peptides are those wherein any of the constituent amino acid residues have not been chemically modified at all in comparison to the natural form; they do not include the (2) PTH analogs discussed later. Concrete examples of partial peptides include human PTH (1-34), human PTH (1-35), human PTH (1-36), human PTH (1-37), human PTH (1-38), human PTH (1-84), and the like, all of which have a sequence of 34-84 amino acids. Specifically, human PTH (1-34) is a partial peptide of the natural form sequence corresponding to amino acids numbers 1-34 of natural human PTH. Human PTH (1-34) and human PTH (1-84) are preferred, and human PTH (1-34) is especially preferred. The amino acid sequence of human PTH (1-34) is as follows:
(21) TABLE-US-00001 [ChemicalFormula4] (SEQIDNO:4) H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH
(22) The PTH peptide of the present invention may also be present as a salt formed with one or more volatile organic acids. Examples of volatile organic acids include trifluoroacetic acid, formic acid, acetic acid, and the like. Acetic acid can be given as a preferred example, but preferred examples are not limited to this. The ratio of the two when free PTH peptide and a volatile organic acid form a salt is not particularly restricted as long as a salt forms. For example, since human PTH (1-34) has nine basic amino acid residues and four acidic amino acid residues in its molecule, taking into consideration salt formation in these molecules, the basic amino acid 5 residue can be made into a chemical equivalent of acetic acid. For example, if an acetic acid content represented by the acetic acid weight100(%)/peptide weight of human PTH (1-34) is used as the amount of acetic acid, as one theory, the chemical equivalent of acetic acid versus free human PTH (1-34) becomes approximately 7.3% (wt %). In this specification, free human PTH (1-34) sometimes is also called teriparatide, and the acetate of teriparatide is sometimes also called teriparatide acetate. The acetic acid content in teriparatide acetate is not particularly restricted as long the teriparatide and acetic acid form a salt. For example, it may be 7.3%, which is the above theoretical chemical equivalent, or higher, or it may be from more than 0% to less than 1%. More concrete examples of the acetic acid content in teriparatide acetate are 1-7%, preferably 2-6%.
(23) However, regardless of whether the PTH peptide of the present invention is a free compound or a salt thereof, the amount of PTH peptide in the preparation of the present invention, amount of various PTH analogs, amount of PTH analog mixture, and total PTH analogs can be determined by HPLC testing. It should be noted that in this case the PTH peptide and PTH analogs are all determined as free compounds.
(24) (2) PTH Analogs
(25) The term PTH analog in the present invention is defined in the broad sense as one detected as a peak different from the PTH peptide which is the active ingredient on the chromatogram when a sample from a freeze-dried preparation containing PTH peptide is subjected to HPLC. Therefore, if detected as one peak different from the original PTH peptide on the chromatogram, all of the chemical substances included in this peak may be regarded together as a single PTH analog even when two or more separate chemical substances are present in mixture within the peak. That is, for the purposes of general measurement and confirming the purity of a freeze-dried preparation, even a mixture of multiple chemical substances detectable as a single peak on the HPLC chromatogram is comprehensively termed an analog and confirmation of purity, calculation of purity, and the like are broadly performed regarding a single peak consisting of such a mixture as one analog for the sake of convenience. There is consequently no problem with regarding a mixture of multiple chemical substances detected as a single peak in HPLC under given conditions comprehensively as one type of PTH analog.
(26) In the present invention, the PTH analogs discovered to be produced during the production of a freeze-dried preparation containing PTH peptide were characterized as shown in Table 1 below.
(27) TABLE-US-00002 TABLE 1 Characterization of PTH analogs Fragment Overview of changed Amino changes (trypsin acid Change Nature of Estimated structural Analog digestion) changed in mass change changes 1 T1 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 T2 Met 18 16 Da Oxidation [O]-Met 18 [O]-Trp 23 T3 Trp 23 32 Da a) [dioxidation] 2 T1 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 T2 Met 18 16 Da Oxidation [O]-Met 18 [O]-Trp 23 T3 Trp 23 4 Da b) [dioxidation-formic acid elimination] 3 T1 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 T2 Met 18 16 Da Oxidation [O]-Met 18 [O] 4 T1 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 T3 Trp 23 32 Da a) [O]-Trp 23 [dioxidation] 5 T2 Met 18 16 Da Oxidation Human PTH (1-34)-Met 18 T3 Trp 23 32 Da a) [O]-Trp 23 [dioxidation] 6 T2 Met 18 16 Da Oxidation Human PTH (1-34)-Met 18 T3 Trp 23 4 Da b) [O]-Trp 23 [dioxidation-formic acid elimination] 7 T1 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 [O] 8 T2 Met 18 16 Da Oxidation Human PTH (1-34)-Met 18 [O] 9 T3 Trp 23 32 Da a) Human PTH (1-34)-Trp 23 [dioxidation] 10 T3 Trp 23 16 Da c) Human PTH (1-34)-Trp 23 [monoxidation] 11 T3 Trp 23 4 Da b) Human PTH (1-34)-Trp 23 [dioxidation-formic acid elimination]
(28) In the above Table 1, T1-T3 are typical fragments produced when each analog is digested by trypsin and are as follows when listed based on the amino acid sequence of the human PTH (1-34) sequence.
(29) TABLE-US-00003 [ChemicalFormula5] T1:(correspondingtopositions1-13ofhumanPTH (1-34) (SEQIDNO:1) Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys T2:(correspondingtopositions14-20ofhumanPTH (1-34) (SEQIDNO:2) His-Leu-Asn-Ser-Met-Glu-Arg T3:(correspondingtopositions21-25ofhumanPTH (1-34) (SEQIDNO:3) Val-Glu-Trp-Leu-Arg
(30) The numbers of the amino acids changed in Table 1 are expressed as the corresponding amino acid numbers of the human PTH (1-34) sequence. The same notation is used in this specification unless otherwise indicated.
(31) In the estimated structures of Table 1, human PTH (1-34)-Met 8 [O]-Met 18 [O]-Trp 23 [dioxidation] (analog 1) means a PTH analog in which the residues corresponding to the position 8 and 18 methionine of human PTH (1-34) are each methionine sulfoxide residues, the residue corresponding to the position 23 tryptophan is a residue shown by the following structure (a) (Trp 23 oxidation (a) residue), and the other structures are the same as the original PTH peptide.
(32) ##STR00004##
(33) Human PTH (1-34)-Met 8 [O]-Met 18 [O]-Trp 23 [dioxidation-formic acid elimination] (analog 2) means a PTH analog in which the residues corresponding to the position 8 and 18 methionine of human PTH (1-34) are each methionine sulfoxide residues, the residue corresponding to the position 23 tryptophan is a residue shown by the following structure (b) (Trp 23 oxidation (b) residue), and the other structures are the same as the original PTH peptide.
(34) ##STR00005##
(35) Similarly, human PTH (1-34)-Met 8 [O]-Met 18 [O] (analog 3) means a PTH analog in which residues corresponding to the position 8 and 18 methionine of human PTH (1-34) are each methionine sulfoxide residues and the other structures are the same as the original PTH peptide. Human PTH (1-34)-Met 8 [O]-Trp 23 [dioxidation] (analog 4) means a PTH analog in which the residue corresponding to the position 8 methionine of human PTH (1-34) is a methionine sulfoxide residue, the residue corresponding to the position 23 tryptophan is a Trp 23 oxidation (a) residue, and the other structures are the same as the original PTH peptide. Furthermore, analog 3 and analog 4 tend to be detected as a single peak, depending on the HPLC conditions. In this case, the PTH analog may be defined as a mixture of analog 3 and analog 4 as discussed above.
(36) Human PTH (1-34)-Met 18 [O]-Trp 23 [dioxidation] (analog 5) means a PTH analog in which the residue corresponding to the position 18 methionine of human PTH (1-34) is a methionine sulfoxide residue, the residue corresponding to the position 23 tryptophan is a Trp 23 oxidation (a) residue, and the other structures are the same as the original PTH peptide.
(37) Human PTH (1-34)-Met 18 [O]-Trp 23 [dioxidation-formic acid elimination] (analog 6) means a PTH analog in which the residue corresponding to the position 18 methionine of human PTH (1-34) is a methionine sulfoxide residue, the residue corresponding to the position 23 tryptophan is a Trp 23 oxidation (b) residue, and the other structures are the same as the original PTH peptide.
(38) Human PTH (1-34)-Met 8 [O] (analog 7) means a PTH analog in which the residue corresponding to the position 8 methionine of human PTH (1-34) is a methionine sulfoxide residue and the other structures are the same as the original PTH peptide.
(39) Human PTH (1-34)-Met 18 [O] (analog 8) means a PTH analog in which the residue corresponding to the position 18 methionine of human PTH (1-34) is a methionine sulfoxide residue and the other structures are the same as the original PTH peptide.
(40) Human PTH (1-34)-Trp 23 [dioxidation] (analog 9) means a PTH analog in which the residue corresponding to the position 23 tryptophan of human PTH (1-34) is a Trp 23 oxidation (a) residue and the other structures are the same as the original PTH peptide.
(41) Human PTH (1-34)-Trp 23 [monoxidation] (analog 10) means a PTH analog in which the residue corresponding to the position 23 tryptophan of human PTH (1-34) is a residue shown by the following structure (c)-1 or (c)-2 (Trp 23 oxidation (c) residue) residue and the other structures are the same as the original PTH peptide.
(42) ##STR00006##
(43) Human PTH (1-34)-Trp 23 [dioxidation-formic acid elimination] (analog 11) means a PTH analog in which the residue corresponding to the position 23 tryptophan of human PTH (1-34) is a Trp 23 oxidation (b) residue and the other structures are the same as the original PTH peptide. Furthermore, analog 10 and analog 11 tend to be detected as a single peak, depending on the HPLC conditions. In this case, the PTH analog may be defined as a mixture of analog 10 and analog 11 as discussed above
(44) In the above analogs 1 to 11, the PTH peptide changes in that modified amino acid residues produced by oxidation of either methionine or tryptophan are introduced. It is therefore logical to assume that the production of the PTH analogs of the present invention is begun by contact between a substance having oxidizing capability and the PTH peptide. In this specification, a substance having oxidizing capability means a substance having the capacity to oxidize a structural amino acid of the PTH peptide, especially methionine or tryptophan. Given that ozone, formaldehyde, and other such oxidizing gaseous molecules are sometimes present in the air inside a pharmaceutical production facility, as discussed above, such substances capable of oxidizing methionine and tryptophan which may be contained in the air inside a pharmaceutical production facility are of interest as substances having oxidizing capability in this specification.
(45) Furthermore, as is evident from the above, the above definition of PTH analogs can be applied even when the PTH peptide contained as an active ingredient is other than human PTH (1-34). For example, when human PTH (1-84) is used as an active ingredient, the corresponding analog 1 can also be expressed as human PTH (1-84)-Met 8 [O]-Met 18 [O]-Trp 23 [dioxidation]. In this case, the analog can be specified as one in which the position 8 and 18 methionine residues of human PTH (1-84) are each methionine sulfoxide residues, the position 23 tryptophan residue is a Trp 23 oxidation (a) residue, and the other structures are the same as human PTH (1-84).
(46) (3) Detection and Determination of PTH Analogs
(47) The PTH analogs in a freeze-dried preparation containing PTH can be detected or determined by producing a sample by dissolving the preparation in a suitable solvent (phosphate buffer containing benzalkonium chloride or the like) and subjecting this sample to HPLC under, for example, the following conditions.
(48) <HPLC Conditions>
(49) a) Detector: Ultraviolet absorptiometer (measurement wavelength: 214 nm)
(50) b) Column: Stainless steel tube 150 mm long having an inner diameter of 4.6 mm packed with 3.5 m of octadecylsilylated silica gel for liquid chromatography (Zorbax 300SB-C18 manufactured by Agilent Technologies or an equivalent product)
(51) c) Column temperature: Constant temperature near 40 C.
(52) d) Mobile phase:
(53) Mobile phase A: Dissolve 28.4 g of anhydrous sodium sulfate in 900 mL of water and bring to 1000 mL by adding water after adding phosphoric acid to adjust the pH to 2.3. Add 100 mL of acetonitrile to this 900 mL of liquid.
(54) Mobile phase B: Dissolve 28.4 g of anhydrous sodium sulfate in 900 mL of water and bring to 1000 mL by adding water after adding phosphoric acid to adjust the pH to 2.3 Add 500 mL of acetonitrile to 500 mL of this liquid.
(55) e) Mobile phase feed: Concentration gradient control is provided by varying the mixture ratio of mobile phase A and mobile phase B as shown in Table 2.
(56) TABLE-US-00004 TABLE 2 Concentration gradient control Time after sample injection (min) Mobile phase A (vol %) Mobile phase B (vol %) 0-5 100.fwdarw.65 0.fwdarw.35 5-35 65.fwdarw.60 35.fwdarw.40 35-45 60.fwdarw.0 40.fwdarw.100
(57) f) Flow rate: 1.0 mL/min
(58) g) Detection time: 45 minutes after injection of the sample solution. However, this is from the back of the solvent peak.
(59) Since the PTH peptide and PTH analogs of the present invention have substantial absorbance in the ultraviolet region, monitoring the ultraviolet absorption is advantageous for their detection and determination. The measurement wavelength is not particularly restricted as long as it allows detection of the PTH peptide and PTH analogs. One or more wavelengths may be selected, for example, in the range of 210-360 nm, preferably 210-280 nm, and more preferably 210-254 nm. One example of a suitable wavelength is 214 nm. A chromatogram can be produced based on the measured values of this ultraviolet absorption.
(60) The amount of each PTH analog and the amount of PTH peptide can be determined by calculating each peak area (e.g., by automatic integration) on the chromatogram based on the chromatogram obtained by performing HPLC as discussed above. The amount of each PTH analog (%) and the total amount of PTH analogs (%) can then be determined and compared based on the calculated values by the following formulas 1 and 2. Furthermore, the total peak area in the formulas is a value determined by adding the peak area of PTH peptide and the peak areas of all other PTH analogs detected on the chromatogram. Therefore, the total peak area corresponds to the sum of the amount of PTH peptide and total amount of PTH analogs. In addition, unless specifically indicated otherwise, % has the meaning of the following formula in the present invention.
Amount of each PTH analog (%)=(peak area of each analog/total peak area)100<Formula 1>
Total amount of PTH analogs (%)=(sum total of peak areas of each analog/total peak area)100<Formula 2>
(61) Furthermore, analogs 3 and 4 (analogs 3 and 4) produced from human PTH (1-34) elute as a single peak, as was mentioned above, when HPLC is carried out under the above conditions. Since regarding this single peak as one analog does not affect the results when used to confirm the purity or measure the preparation in this case, the mixed peak of analogs 3 and 4 (analogs 3 and 4) may be regarded as one analog. The same is also true of analogs 10 and 11 (analogs 10 and 11).
(62) Table 3 below shows a typical measurement example when HPLC was performed under the above conditions on a sample derived from a freeze-dried preparation containing human PTH (1-34). Furthermore, the notation approximate relative retention time in the table is because the relative retention time also sometimes changes depending on the column used or the mobile phase flow rate. Nonetheless, each analog can be identified and determined based on the pattern of the chromatogram taking this relative retention time as a criterion even in this case.
(63) TABLE-US-00005 TABLE 3 HPLC measurement example Approximate relative retention time, taking the retention time PTH analog of human PTH (1-34) as 1.00 (1) Human PTH (1-34)-Met 8 [O]-Met 0.49 18 [O]-Trp 23 [dioxidation] (2) Human PTH (1-34)-Met 8 [O]-Met 0.50 18 [O]-Trp 23 [dioxidation-formic acid elimination] (3) Mixture containing human PTH (1- 0.52 34)-Met 8 [O]-Met 18 [O] and human PTH (1-34)-Met 8 [O]-Trp 23 [dioxidation] (4) Human PTH (1-34)-Met 18 [O]-Trp 0.55 23 [dioxidation] (5) Human PTH (1-34)-Met 18 [O]-Trp 0.57 23 [dioxidation-formic acid elimination] (6) Human PTH (1-34)-Met 8 [O] 0.60 (7) Human PTH (1-34)-Met 18 [O] 0.66 (8) Human PTH (1-34)-Trp 23 0.69 [dioxidation] (9) Mixture containing human PTH (1- 0.74 34)-Trp 23 [monoxidation] and human PTH (1-34)-Trp 23 [dioxidation- formic acid elimination]
(64) (4) Freeze-Dried Preparation Containing PTH Peptide
(65) A freeze-dried preparation containing PTH peptide of the present invention means a freeze-dried preparation containing PTH peptide as an active ingredient.
(66) One embodiment of the freeze-dried preparation containing PTH peptide of the present invention is a freeze-dried preparation containing PTH peptide wherein the amount of a PTH analog in the preparation is 1.0% or less versus the sum of the amount of PTH peptide and total amount of PTH analogs and/or the total amount of PTH analogs in the preparation is 5.0% or lower versus the sum of the amount of PTH peptide and total amount of PTH analogs.
(67) Another embodiment of the freeze-dried preparation containing PTH peptide of the present invention is a freeze-dried preparation containing PTH peptide wherein the amount of any of the respective PTH analogs is 1.0% or less versus the sum of the amount of PTH peptide and total amount of PTH analogs and/or the total amount of PTH analogs in the preparation is 5.0% or lower versus the sum of the amount of PTH peptide and total amount of PTH analogs. Furthermore, 1.0% or less and 5.0% or less mean when absolutely no PTH analogs are contained in the freeze-dried preparation containing PTH peptide of the present invention or when that % or less is contained.
(68) Preferably, the freeze-dried preparation containing PTH peptide of the present invention does not contain any more than 1.0% of at least one or more PTH analogs versus the sum of the amount of PTH peptide and total amount of PTH analogs, and more preferably does not contain more than 1.0% of any PTH analog versus the sum of the amount of PTH peptide and total amount of PTH analogs. In addition, when two analogs give a single peak on the chromatogram, as mentioned above, the single peak is regarded as one analog, and the analog regarded in this way is more preferably not contained in an amount exceeding 1.0% versus the sum of the amount of PTH peptide and total amount of PTH analogs. The amount of each PTH analog in the preparation is preferably 1.0% or less, but 0.9% or less, 0.8% or less, 0.7% or less, and 0.6% or less are also preferred. Moreover, the total amount of PTH analogs is preferably 5.0% or less, but 4.5% or less, 4.0% or less, 3.5% or less, and 3.0% or less are also preferred.
(69) An example of a suitable freeze-dried preparation containing PTH peptide of the present invention appears below as Table 4. (Furthermore, the total amount of PTHs in the table means the sum of the amount of PTH peptide and total amount of PTH analogs.)
(70) TABLE-US-00006 TABLE 4 Suitable freeze-dried preparation containing PTH peptide of the present invention Content versus total amount of PTHs PTH analog (%) (1) PTH-Met 8 [O]-Met 18 [O]-Trp 23 0.04% or less, preferably 0.03% or [dioxidation] less (e.g. Human PTH (1-34)-Met 8 [O]-Met 18 [O]-Trp 23 [dioxidation]) (3) Mixture containing PTH-Met 8 0.11% or less, preferably 0.10% or [O]-Met 18 [O] and PTH-Met 8 [O]- less, most preferably 0.03% or less Trp 23 [dioxidation] (e.g., Mixture containing human PTH (1-34)-Met 8 [O]-Met 18 [O] and human PTH (1-34)-Met 8 [O]-Trp 23 [dioxidation]) (4) PTH-Met 18 [O]- Trp 23 0.26% or less, preferably 0.20% or [dioxidation] less, most preferably 0.06% or less (e.g., Human PTH (1-34)-Met 18 [O]- Trp 23 [dioxidation]) (6) PTH-Met 8 [O] 0.33% or less, preferably 0.30% or (e.g., Human PTH (1-34)-Met 8 [O]) less, most preferably 0.23% or less (7) PTH-Met 18 [O] Arbitrary percentage selected from (e.g., Human PTH (1-34)-Met 18 [O]) 1.01-2.00% or less, preferably 1.00% or less, more preferably 0.50% or less, most preferably 0.36% or less (8) PTH-Trp 23 [dioxidation] 0.68% or less, preferably 0.50% or (e.g., Human PTH (1-34)-Trp 23 less, most preferably 0.11% or less [dioxidation])
(71) To further explain the freeze-dried preparation containing PTH peptide of the present invention, the freeze-dried preparation containing PTH peptide of the present invention can contain various additives. Examples of additives include sugars, amino acids, sodium chloride, and the like. When sugars are used as additives, mannitol, glucose, sorbitol, inositol, sucrose, maltose, lactose, or trehalose is preferably added in an amount of 1 weight or more (preferably 50-1000 weights) per weight of PTH peptide. When sugars and sodium chloride are used as additives, sodium chloride is preferably added in an amount of 1/1000- weight (preferably 1/100 to 1/10 weight) per weight of sugars.
(72) (5) Container of the Freeze-Dried Preparation Containing PTH Peptide of the Present Invention
(73) The container used for the freeze-dried preparation containing PTH peptide of the present invention is not particularly restricted, but the preparation is preferably a freeze-dried preparation containing PTH peptide housed in a stoppered glass container. The material of the stopper is not particularly restricted, but rubber is preferred. The stopper is preferably washed, sterilized, and/or dried.
(74) The freeze-dried preparation containing PTH peptide of the present invention housed in a stoppered glass container is, for example, a freeze-dried preparation containing PTH peptide housed in a glass vial having a rubber stopper (glass vial preparation), kit preparation comprising a freeze-dried preparation containing PTH peptide housed in a glass vial having a rubber stopper and an ampule sterilely filled with aqueous solution for dissolution, kit preparation comprising a freeze-dried preparation containing PTH peptide and prefilled syringe sterilely filled with aqueous solution for dissolution, or glass double chamber preparation (two chambers are present in one syringe, one chamber containing freeze-dried preparation containing PTH peptide and the other containing aqueous solution for dissolution). A glass vial preparation is most preferred as the freeze-dried preparation containing PTH peptide of the present invention. Examples of the material of the rubber stopper include chlorinated butyl rubber, normal butyl rubber, butadiene rubber, isoprene rubber, silicone rubber, elastomer, and the like. Silicate glass is preferred as the glass.
(75) (6) Production of a Freeze-Dried Preparation Containing PTH Peptide
(76) A freeze-dried preparation is produced by a process typically including any or all of the following steps, depending on its use. Unless particularly stated otherwise, the freeze-dried preparation containing PTH peptide of the present invention can also be produced according to the following steps. Specifically the production scheme of the freeze-dried preparation containing PTH peptide of the present invention includes at least an active ingredient-containing solution preparation step and a freeze drying step explained below. It usually includes an active ingredient-containing solution preparation step, loading step, and freeze drying step, and preferably includes an active ingredient-containing solution preparation step, aseptic filtration and drug solution dispensing step, loading step, freeze drying step, and packaging step.
(77) 1) Active Ingredient Solution Preparation Step
(78) This step dissolves a bulk compound of the active ingredient and various additives as needed in a solvent (e.g., water for injection). Adjustment of the pH of the solution, adjustment of the volume of the solution, and the like may be performed as needed. The time necessary for this step is not particularly restricted as long as it is within the acceptable range for industrial production, but it may be 0.5-5 hours, usually about 1-3 hours.
(79) When the PTH peptide of the present invention is the active ingredient, it is preferable to dissolve the bulk PTH peptide in advance and add it to a solution in which the various additives have been dissolved. Examples of additives include excipients, stabilizers, dissolution auxiliaries, antioxidants, analgesics, isotonifying agents, pH regulators, and preservatives.
(80) 2) Aseptic Filtration and Drug Solution Dispensing Step
(81) This step includes aseptic filtration of the active ingredient-containing solution prepared in the above step and filling a container suited to the performance of the freeze drying step explained below with this aseptic filtered solution (drug solution).
(82) In a typical step, aseptic filtration is carried out using a filter. Various commercial products can be used as the filter for aseptic filtration. The pore size of the filter is preferably 0.2 m or less or 0.22 m or less. Specific equipment and the like for performing aseptic filtration is well known to those skilled in the art. Such aseptic filtration makes it possible to prepare a drug solution for producing a freeze-dried preparation to be utilized as a pharmaceutical.
(83) Typical drug solution filling in this step is also well known to those skilled in the art. Usually, individual containers are filled directly with drug solution after aseptic filtration of the solution of the active ingredient. Alternatively, a large amount of solution may be aseptically filtered at once and subsequently dispensed into containers suited to use in the following step. An example of these containers is a glass vial that can be stoppered by a rubber stopper or the like. The use of such glass vials is advantageous in the production of a preparation in a glass vial.
(84) The time necessary for this step is also not particularly restricted as long as it is within the acceptable range for industrial production, but it may be 0.5-2 hours, usually 0.5-1 hour, as the filtration step and 3-10 hours, usually 6-10 hours, as the filling step.
(85) Furthermore, when the freeze-dried preparation containing PTH peptide of the present invention is made into a preparation in a glass vial, one glass vial can be filled, for example, with about 1 g (preferably 0.3-3 g, more preferably 0.5-0.6 g) of aseptically filtered solution containing PTH peptide.
(86) 3) Loading Step
(87) The term loading step here means a series of steps whereby the filled containers prepared as described above are transported (transferred) to the freeze-drying means used in the next step and loaded and placed in that means.
(88) The stoppers of the filled containers are usually open or partially open to dry by vacuum the filled solution frozen in a subsequent step in the production of a freeze-dried preparation. An open stopper means that the stopper is completely open, and a partially open stopper means that the stopper is not open but not closed. This makes it possible to vacuum dry the drug solution in the container after freezing. For example, when the product is a preparation in a glass vial, a partially open stoppered state as above is created by stoppering the filled vial partially using a rubber stopper after filling the glass vial by aseptically filtered solution (drug solution). When the freeze-dried preparation containing PTH peptide of the present invention is made as a preparation in a glass vial or the like, a step to provide partial stoppering in this way is also included in this loading step.
(89) A freeze drying means is means making it possible to dry the frozen solution under vacuum. Means for industrial production is preferably also provided with an adequate cooling function to freeze the solution or preferably provided with a function to properly heat the material to be freeze dried during this treatment to accelerate freeze drying. Since the material to be freeze dried is loaded into a chamber in a typical freeze-drying means suited to industrial production, this means has a large door (also referred to as large door hereinafter) corresponding to basically its entire front surface. A typical freeze-drying means is a freeze-drying chamber (also called a freeze dryer), and many forms of these are marketed.
(90) To explain this step by way of example, taking a preparation in glass vials as an example of the preparation to be produced, a process whereby glass vials filled with drug solution obtained in the above step 2) are partially stoppered and transported to the freeze-drying means and each vial is loaded sequentially or a quantity unit is loaded together at one time into the freeze-drying chamber and placed therein corresponds to this step. Furthermore, when it is noted here that each vial is loaded sequentially, depending on the layout of the pharmaceutical production facility, this can mean that each vial is filled one after another continuously by the above drug solution dispensing step, and each vial is then sequentially partially stoppered and transferred (transported) to the freeze-drying means. Usually, however, since the process moves to the next freeze-drying step after all of the vials that can be treated at once by the freeze-drying means have been loaded into the freeze-drying means, each of the vials transported as described above is introduced one after another (that is, sequential loading) and placed into the freeze-drying means until reaching the quantity that can be treated at once. However, in the case of such sequential loading, the loading step of the present invention means a step that begins with a certain (first) vial after the drug solution dispensing step has been completed until the final vial to be freeze dried together with this (first) vial (that is, at once) has been loaded and placed in the freeze-drying means.
(91) Loading the vials in a quantity unit together at one time can mean, for example, that there are multiple trays in the freeze-drying chamber and multiple drug solution-filled vials are placed together on each tray when placing them in the freeze-drying chamber, and sometimes these trays can be moved up and down for the sake of convenience when loading the drug solution-filled vials. In this case as well, the loading step of the present invention means a step that begins with a certain (first) vial after the drug solution dispensing step has been completed until the final vial to be freeze dried together with this (first) vial has been loaded and placed in the freeze-drying means. In any case, the drug solution-filled vials are left in a partially open state in this step until the subsequent freeze drying step begins and may be exposed to the air environment within a pharmaceutical production facility explained below.
(92) The time necessary for this step also is not particularly restricted as long as it is within the range acceptable for industrial production, but is 3-10 hours, usually about 6-10 hours.
(93) 4) Freeze Drying Step
(94) This is a step for sublimating water from the frozen material to be dried under reduced pressure by the above freeze drying means. When a freeze-dried preparation is produced in glass vials, the vials can be placed in an open or partially open state under reduced pressure (for example, with the vials partially stoppered), and sealed at the end of freeze drying after the space in the vial has been purged by nitrogen.
(95) The time necessary for this step varies depending on the capabilities of the freeze drying means, amount of substance to be freeze dried, and the like and should be within the range acceptable for industrial production. It is usually about 24-72 hours.
(96) 5) Closing Step
(97) This step can be included when producing a freeze-dried preparation in a glass vial. Specifically, it is a step whereby the freeze-dried glass vials obtained in the above step 4) are closed by an aluminum cap by a press-type capping machine, or the like.
(98) 6) Packaging Step
(99) This is a step that attaches a label to the preparation and packages it in a paper box or the like.
(100) When a freeze-dried preparation is produced as a pharmaceutical, the production facility must be a facility that meets the pharmaceutical GMP. This facility has drug solution preparation equipment, aseptic filtration equipment, and freeze drying equipment (means) and, in addition to these, water for injection production equipment, vial filling and stoppering equipment, capping machines, labelers, and the like to implement the steps explained above.
(101) When a freeze-dried preparation is produced as a pharmaceutical, all of the above steps 1)-6) or at least from the end of the aseptic filtration step to the beginning of the freeze drying step should be carried out in air environments within a pharmaceutical production facility. That is, the air environment of the pharmaceutical production facility differs from the simple outside air environment. Specifically, it is required that the air environment inside a facility for production of a sterile injection (pharmaceutical) be a critical area of high cleanliness (the content of suspended microparticles 0.5 m or greater in size per m.sup.3 of air is to be 3520 or fewer during both work and non-work times). This air quality corresponds to grade A (termed class 100 or ISO 5) according to current, commonly-used domestic and international air quality standards.
(102) The air environment inside the facility that produces a freeze-dried preparation containing PTH peptide of the present invention should be at least equivalent to the air environment inside the above sterile injection production facility, more preferably an environment that maintains a unidirectional flow downward from above of clean air that has passed through HEPA filters capable of trapping particles of 0.3 m in size at an efficiency of 99.97% or greater. The air flow speed is preferably 0.2-1.0 m/s at a location 20 cm below the HEPA filter and 0.1-0.8 m/s at the location where the production work is carried out, more preferably 0.4-0.7 m/s at a location 20 cm below the HEPA filter and 0.3-0.5 m/s at the location where the production work is carried out.
(103) To create a more sterile air environment inside a pharmaceutical production facility, bacteria suspended in the air and bacteria adhered to machinery, walls, floors, and other such installations are sterilized using ozone or formaldehyde or chemicals having oxidizing capability, such as hydrogen peroxide, peracetic acid, chlorine dioxide, glutaraldehyde, and the like, as disinfectants. The residual formaldehyde concentration after fumigation and sterilization by formaldehyde should usually be kept to 0.1 ppm or lower, preferably 0.08 ppm or lower. Furthermore, in terms of ozone, ozone is usually present even in the outside air in a concentration of 0.001-0.02 ppm as an average daily value. Concentrations of approximately 0.02-0.1 ppm are also sometimes present temporarily depending on the time, location, and season.
(104) As one embodiment of the present invention, a method for producing a freeze-dried preparation containing PTH peptide is characterized in that exposure of the solution containing PTH peptide to the air environment within a pharmaceutical production facility is controlled during the process of the course when a substantial time is required under the air environment within a pharmaceutical production facility as described above at the beginning of the step for preparing a solution of PTH peptide (active ingredient), especially from the end of the drug solution dispensing step to the beginning of the drug solution freeze drying step (that is, loading step).
(105) In the present invention, exposure to air environments within a pharmaceutical production facility is controlled and control of exposure to air environments within a pharmaceutical production facility mean both that at least one or more of the PTH peptide bulk drug, solution containing PTH peptide, and PTH peptide freeze-dried preparation have absolutely no contact with air environments within a pharmaceutical production facility and that this contact is substantially (e.g., time and level of contact) restricted. For example, in the case of an environment in which clean air that has passed through HEPA filters as described above is maintained as a unidirectional flow in a direction downward from above (referred to hereinafter as flowing air), this includes provision of a means to control the time in contact with this flowing air and the contacted air flow rate. Specific examples appear below.
(106) (A) Means to Control Contact of the Solution Containing PTH Peptide with Flowing Air
(107) As described above, the present inventors discovered that the generation of impurities (PTH analogs) in solution containing PTH peptide can be controlled by providing means for controlling contact of the solution containing PTH peptide with flowing air. Since flow of the air within the facility is maintained in an ordinary pharmaceutical production facility, it can be deduced that a large amount of air that pours down as air flow comes into contact with the solution containing PTH peptide and that gaseous substances having oxidizing capability (ozone and the like) contained in this air flow increase the PTH analogs in the solution by causing reactions and the like with the PTH peptide in the solution.
(108) The means for controlling contact of the solution containing PTH peptide with flowing air in the present invention is not particularly restricted. Examples include a means for controlling the fluidity and flow of the air in the vicinity of the solution containing PTH peptide and a means for purging the vicinity of the solution containing PTH peptide with an inert gas.
(109) It was also discovered that it is advantageous to provide means for controlling contact of the solution containing PTH peptide with flowing air in the loading step into the freeze-drying chamber.
(110) To explain the above embodiment based on a non-limiting example, an ordinary freeze-drying chamber has a door in the front surface for loading the containers filled with the solution to be freeze dried. This door is often a door (large door) that can cover the entire front surface of the freeze-drying chamber. The present invention, however, at a part of the large door, additionally provides a small door of a size roughly corresponding to one of the trays placed in the freeze-drying chamber (with the filled containers to be freeze dried disposed on top of it), and a freeze-drying chamber having a small door that can be opened and closed easily to load the containers is preferred.
(111) A more preferred example is the above freeze-drying chamber with a small door having sub-doors that can be opened and closed easily provided with openings for loading (also referred to hereinafter as small door openings) to create small door units to open when loading and unloading the containers filled with the material to be freeze dried into the freeze-drying chamber and a means to open the sub-door only during container loading without leaving it constantly open and to close it quickly after loading. These sub-doors are provided divided into 2-5 levels among the zones corresponding to the small door openings so that only the necessary unit may be opened for loading. Sub-doors that make it possible to open only the necessary location for loading the containers are preferred, and division into 2-3 levels is preferred. Examples of sub-doors that can opened and closed easily include a sub-door that provides a hinge (hinge) at the top of the sub-door and is installed in the small door opening, a sub-door that slides to the right and left, a sub-door that slides up and down, and the like.
(112) Preferred examples of other means of controlling contact of the solution containing PTH peptide and the like with flowing air include sealing the equipment for preparation (tank or container and the like) after the PTH peptide has been dissolved in the solvent in the solution containing PTH peptide preparation step or purging the interior of the container used for preparation by an inert gas during preparation.
(113) The inside of the preparation equipment (tank or container and the like) is sometimes pressurized and the prepared solution containing PTH peptide is passed through a sterile filter and fed to the container or tank for dispensing in the aseptic filtration and drug solution dispensing step. Another preferred example of a means for controlling contact of the solution containing PTH peptide with flowing air is to use an inert gas as the gas for pressurization in this case.
(114) Another preferred example of a means for controlling contact of the solution containing PTH peptide with flowing air is to purge the air inside the drug solution dispensing equipment (tank or container and the like) with an inert gas in advance in the aseptic filtration-drug solution dispensing step and to purge the glass container to be filled with the solution containing PTH peptide with an inert gas in advance.
(115) Alternatively, another preferred example of means for controlling contact of the solution containing PTH peptide with flowing air is to purge the space inside the glass container (part containing air and no drug solution) filled with the solution containing PTH peptide with an inert gas in the aseptic filtration-drug solution dispensing step.
(116) Furthermore, the glass containers filled with the solution containing PTH peptide are sometimes transported from the aseptic filtration-drug solution dispensing equipment to near the freeze-drying chamber during the time after the end of the aseptic filtration-drug solution dispensing step up to loading of the solution containing PTH peptide housed in the open or partially open glass containers into the freeze drying means. Placing the environment during transport under an inert gas flow can also be given as a preferred example of a means for controlling contact of the solution containing PTH peptide with flowing air in such cases.
(117) Alternatively, a flap or airflow-adjusting cover (
(118) In addition to purging means using inert gas as described above, the means for purging the vicinity of the solution containing PTH peptide with inert gas can be means for purging the air inside the freeze-drying chamber used in the freeze drying step using an inert gas or means for causing an inert gas to flow from the loading port into the freeze-drying chamber when loading the containers of solution containing PTH peptide into the freeze-drying chamber used in the freeze drying step. The flow rate of the inert gas during influx is preferably 0.1-5 Nm.sup.3/min, more preferably 0.2-3 Nm.sup.3/min, and most preferably 0.3-1 Nm.sup.3/min. Examples of the inert gas in purging by an inert gas include nitrogen and argon; nitrogen can be given as a preferred example.
(119) (B) Step that Provides Means for Controlling Contact of the Solution Containing PTH Peptide with Flowing Air
(120) The means for controlling contact of the solution containing PTH peptide with flowing air of (A) above can be provided in all or some steps included from the beginning of the step for preparing a solution containing PTH peptide to the beginning of the freeze drying step of this solution, and may be provided from the beginning of the step for preparing a solution containing PTH peptide. When the method for producing a freeze-dried preparation containing PTH peptide as a pharmaceutical of the present invention includes a step for preparing a solution containing PTH peptide, a step for loading this solution housed in open or partially open glass containers into a freeze-drying chamber, and a freeze drying step, the means of (A) above can be provided in some or all of the step for loading this solution housed in open or partially open glass containers into a freeze-drying chamber.
(121) (C) Duration of the Step that Provides Means for Controlling Contact of the Solution Containing PTH Peptide with Flowing Air
(122) The duration of the step that provides means for controlling contact of the solution containing PTH peptide with flowing air of (A) above can have, for example, as the lower limit, one hour or more, preferably three hours or more, and more preferably six hours or more, and, as the upper limit, 20 hours or less, preferably 12 hours or less, more preferably 10 hours or less, and most preferably nine hours or less. Examples of the duration of the step that provides a means of (A) above include 1-20 hours, preferably 3-12 hours, more preferably 6-10 hours, and most preferably 6-9 hours.
(123) (7) Use of the Freeze-Dried Preparation Containing PTH Peptide
(124) The freeze-dried preparation containing PTH peptide of the present invention can contain a pharmaceutically effective amount of PTH peptide and, for example, the freeze-dried preparation can be dissolved in a suitable solvent at the time of use to make an injection and used in the treatment of osteoporosis.
(125) (8) Method for Controlling the Production of PTH Analogs in Solution Containing PTH Peptide
(126) The method for controlling the production of PTH analogs of the present invention is a method that provides means for controlling contact of at least one of the PTH peptide bulk drug, solution containing PTH peptide, and freeze-dried preparation containing PTH peptide with substances having oxidizing capability, especially with air containing these substances. A preferred example of a method for controlling the production of PTH analogs is to provide a means for purging air in contact with solution containing PTH peptide by an inert gas (preferably nitrogen). A more preferred example is a method for controlling the production of any one or more PTH analogs among the aforementioned analogs 1 to 11 and analogs 1 to 11 by means for controlling contact of the solution containing PTH peptide with flowing air or means for purging the air in contact with the solution containing PTH peptide by an inert gas (preferably nitrogen).
(127) These production control methods can be implemented in freeze-dried preparation production facilities in air environments within pharmaceutical production facilities as described above. For example, their production in the solution can be controlled by means for controlling contact of the solution with flowing air during the course of the process for a predetermined time or longer from the beginning of the step for preparing a solution containing PTH peptide to the beginning of the freeze drying step of this solution. Preferred embodiments of this means are the same as the preferred embodiments of the corresponding methods for production a freeze-dried preparation containing PTH peptide of the present invention.
EXAMPLES
(128) The present invention is explained more concretely below through examples, reference examples, and test examples without limiting the scope of the invention.
Example 1
(129) Approximately 18 kg of approximately 25 C. water for injection was placed in a 50 L stainless steel container. A quantity of 540 g of sucrose and 27 g of sodium chloride were weighed out into the container and dissolved. Next, 3541 mg of human PTH (1-34) as an acetate (lot A; 860 mg, lot B; 2591 mg, lot C; 90 mg) was added and dissolved. A PTH peptide-containing aqueous solution was then obtained by adding water for injection and correcting the weight to 27 kg. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a 50 L stainless steel filling tank previously filled with nitrogen. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment within a pharmaceutical production facility, washed and dried glass vials were filled with 0.56 g of this aseptically filtered PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. Approximately 1000 vials each were lined up on stainless steel trays, and the trays were then transferred to in front of a freeze-drying chamber manufactured by Ulvac (model: DFB, tray areas: 24 m.sup.2) previously filled with nitrogen in a grade A zone. While purging the inside of the freeze-drying chamber by nitrogen, a sub-door that matched the width of the trays (a door equivalent to the sub-door of
Example 2
(130) Approximately 10 kg of approximately 25 C. water for injection was placed in a 20 L stainless steel container. A quantity of 280 g of sucrose and 14 g of sodium chloride were weighed out into the container and dissolved. Next, the weight was corrected to 14 kg by adding water for injection, and an additive solution was prepared. A PTH peptide-containing aqueous solution was obtained by weighing out 1780 mg (lot D) of human PTH (1-34) as an acetate and dissolving it in 13 kg of the additive solution. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a 50 L stainless steel filling tank previously filled with nitrogen. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment within a pharmaceutical production facility, washed and dried glass vials were filled with 0.56 g of this aseptically filtered PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. Approximately 1000 vials each were lined up on stainless steel trays, and the trays were then transferred to in front of a freeze-drying chamber manufactured by Ulvac (model: DFB, tray areas: 24 m.sup.2) previously filled with nitrogen in a grade A zone. While purging the inside of the freeze-drying chamber with nitrogen, a sub-door that matched the width of the trays (a door equivalent to the sub-door of
Example 3
(131) Approximately 19 kg of approximately 25 C. water for injection was placed in a 30 L stainless steel container. A quantity of 460 g of sucrose and 23 g of sodium chloride were weighed out into the container and dissolved. Next, the weight was corrected to 23 kg by adding water for injection, and a placebo solution was prepared. A PTH peptide-containing aqueous solution was obtained by weighing out 2979 mg (lot D) of human PTH (1-34) as an acetate and dissolving it in 22 kg of the placebo solution. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a stainless steel filling tank previously filled with nitrogen. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment within a pharmaceutical production facility, washed and dried glass vials were filled with 0.56 g of this aseptically filtered PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. The partially open vials were transferred to a grade A zone, and all of the vials were loaded over approximately six hours into a freeze-drying chamber manufactured by Ulvac (model: DFB, tray areas: 22 m.sup.2) previously filled with nitrogen made so that air flow from the opening of the small door does not enter the freeze-drying chamber using a vinyl sheet (a sheet equivalent to the airflow-adjusting cover of
Example 4
(132) Approximately 18 kg of approximately 25 C. water for injection was placed in a 50 L stainless steel container. A quantity of 540 g of sucrose and 27 g of sodium chloride were weighed out into the container and dissolved. Next, 3525 mg of human PTH (1-34) as an acetate (lot C; 1880 mg, lot E; 1645 mg) was added and dissolved. A PTH peptide-containing aqueous solution was then obtained by adding water for injection and correcting the weight to 27 kg. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a 50 L stainless steel filling tank previously filled with nitrogen. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment and a formalin concentration brought to 0.08 ppm or lower within a pharmaceutical production facility, washed and dried glass vials were filled with 0.56 g of this PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. Approximately 1000 vials each were lined up on stainless steel trays, and the trays were then transferred to in front of a freeze-drying chamber manufactured by Ulvac (model: DFB, tray areas: 24 m.sup.2) previously filled with nitrogen in a grade A zone. While purging the inside of the freeze-drying chamber by nitrogen, a sub-door that matched the width of the trays (a door equivalent to the sub-door of
Example 5
(133) Approximately 18 kg of approximately 25 C. water for injection was placed in a 50 L stainless steel container. A quantity of 540 g of sucrose and 27 g of sodium chloride were weighed out into the container and dissolved. Next, 3566 mg of human PTH (1-34) as an acetate (lot H) was added and dissolved. A PTH peptide-containing aqueous solution was then obtained by adding water for injection and correcting the weight to 27 kg. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a 50 L stainless steel filling tank previously filled with nitrogen. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment and a formalin concentration brought to 0.08 ppm or lower within a pharmaceutical production facility, washed and dried glass vials were filled with 0.56 g of this PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. Approximately 1000 vials each were lined up on stainless steel trays, and the trays were then transferred to in front of a freeze-drying chamber manufactured by Ulvac (model: DFB, tray areas: 24 m.sup.2) previously filled with nitrogen in a grade A zone. While purging the inside of the freeze-drying chamber with nitrogen, a sub-door that matched the width of the trays (a door equivalent to the sub-door of
Comparative Example 1
(134) Approximately 5000 g of approximately 25 C. water for injection was placed in a 10 L stainless steel container. A quantity of 120 g of sucrose and 6 g of sodium chloride were weighed out into the container and dissolved. Next, 909 mg of human PTH (1-34) as an acetate (lot F; 335 mg, lot G; 574 mg) was added and dissolved. A PTH peptide-containing aqueous solution was then obtained by adding water for injection and correcting the weight to 6000 g. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a stainless steel filling tank. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment within a pharmaceutical production facility, washed and dried vials were filled with 0.56 g of this PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. The partially open vials were transferred to a grade A zone, and all were sequentially loaded over approximately four hours into a freeze-drying chamber manufactured by Ulvac (model: DFB, tray areas: 22 m.sup.2) having a small door. The solution containing PTH peptide was frozen and freeze dried to sublimate off the water under reduced pressure. After the interiors of the glass vials were purged with nitrogen once drying had been completed, the vials were sealed with the rubber stoppers, capped with aluminum caps, and a freeze-dried preparation containing PTH peptide was obtained.
Comparative Example 2
(135) Approximately 2000 g of approximately 25 C. water for injection was placed in a 10 L stainless steel container. Quantities of 100 g of sucrose and 5 g of sodium chloride were weighed out into the container and dissolved. Next, 515 mg of human PTH (1-34) as an acetate (lot D) was added and dissolved. A PTH peptide-containing aqueous solution was then obtained by adding water for injection and correcting the weight to 4000 g. The PTH peptide-containing aqueous solution obtained was aseptically filtered using a filter while pressurizing by nitrogen and fed to a 5 L stainless steel filling tank. Within a zone having a grade A (air speed approximately 0.2-0.4 m/s) environment within a pharmaceutical production facility, washed and dried vials were filled with 0.56 g of this PTH peptide-containing aqueous solution, and partially open vials were obtained using washed and dried rubber stoppers. The partially open vials were transferred to a grade A zone, and all were sequentially loaded over approximately three hours into a freeze-drying chamber having a small door (Kyowa Vacuum Engineering Co., Ltd. (model: RL, tray area: 9 m.sup.2)). The solution containing PTH peptide was frozen and freeze dried to sublimate off the water under reduced pressure. After the interiors of the glass vials were purged with nitrogen once drying had been completed, the vials were sealed with the rubber stoppers, capped with aluminum caps, and a freeze-dried preparation containing PTH peptide was obtained.
Test Example 1
(136) The area percentage method using HPLC is a simple method for assessing the purity of a freeze-dried preparation containing PTH peptide and the amount of analogs. A solution obtained by weighing out 0.25 g of benzalkonium chloride and bringing it to 50 mL by adding 50 mM sulfate buffer (pH 2.3) serves as the loading buffer. Each preparation of the examples and comparative examples is dissolved by 1 mL of physiological saline solution, and a 9:1 mixture of this solution and the loading buffer serves as the sample solution. A quantity of 100 L of sample solution is tested by HPLC under the following conditions. Furthermore, benzalkonium chloride was used to prevent the peptide that is the target of measurement from attaching to the instrument and the like.
(137) <Test Conditions>
(138) Detector: Ultraviolet absorptiometer (measurement wavelength: 214 nm)
(139) Column: Stainless steel tube 150 mm long having an inner diameter of 4.6 mm packed with 3.5 m of octadecylsilylated silica gel
(140) Column temperature: Constant temperature near 40 C.
(141) Mobile phase: Mobile phase A: Dissolve 28.4 g of anhydrous sodium sulfate in 900 mL of water and bring to 1000 mL by adding water after adding phosphoric acid to adjust the pH to 2.3. Add 100 mL of acetonitrile to this 900 mL of liquid.
(142) Mobile phase B: Dissolve 28.4 g of anhydrous sodium sulfate in 900 mL of water and bring to 1000 mL by adding water after adding phosphoric acid to adjust the pH to 2.3 Add 500 mL of acetonitrile to 500 mL of this liquid.
(143) Mobile phase feed: Concentration gradient control is provided by varying the mixture ratio of mobile phase A and mobile phase B as follows.
(144) Time after Injection:
(145) TABLE-US-00007 TABLE 5 Concentration gradient control Time after sample injection (min) Mobile phase A (vol %) Mobile phase B (vol %) 0-5 100.fwdarw.65 0.fwdarw.35 5-35 65.fwdarw.60 35.fwdarw.40 35-45 60.fwdarw.0 40.fwdarw.100
(146) Flow rate: 1.0 mL/min
(147) Sample temperature: Constant temperature near 5 C.
(148) Detection time: 45 minutes after injection of the sample solution. However, this is from the back of the solvent peak.
(149) Calculation method: The amount of each PTH analog and the total amount thereof was determined by performing liquid chromatography under the above conditions, measuring each peak area by automatic integration, and performing calculation using Formulas 1 and 2. Furthermore, the total peak area was the sum total of the area of all peaks detected by performing liquid chromatography under the above conditions. In other words, the total peak area shows the sum total of PTH peptide and all PTH analogs in the preparation.
Amount of each PTH analog (%)=(peak area of each analog/total peak area)100Formula 1:
Total amount of PTH analogs (%)=(sum total of peak areas of each analog/total peak area)100Formula 2:
(150) <Results>
(151) Table 6 shows the results obtained by assessing the amount of analogs of the human PTH (1-34) (bulk drug) used in the examples.
(152) TABLE-US-00008 TABLE 6 Amount of each analog (%) in human PTH (1-34) used as a bulk drug D A B C Ex. 2, E F G H Use in examples and comparative examples Ex. 1 Ex. 1 Ex. 1, 4 CEx 2 Ex. 4 CEx 1 CEx 1 Ex. 5 (1) Human PTH (1-34)-Met 8 [O]-Met 18 [O]- ND ND ND ND ND ND ND ND Trp 23 [dioxidation] (2) Human PTH (1-34)-Met 8 [O]-Met 18 [O]- ND ND ND ND ND ND ND ND Trp 23 [dioxidation-formic acid elimination] (3) Mixture containing human PTH (1-34)- ND ND ND ND ND ND ND ND Met 8 [O]-Met 18 [O] and human PTH (1-34)- Met 8 [O]- Trp 23 [dioxidation] (4) Human PTH (1-34)-Met 18 [O]- Trp 23 ND ND ND ND ND ND ND ND [dioxidation] (5) Human PTH (1-34)-Met 18 [O]- Trp 23 ND ND ND ND ND ND ND ND [dioxidation-formic acid elimination] (6) Human PTH (1-34)-Met 8 [O] 0.08 0.07 0.11 0.05 0.05 0.14 0.17 0.06 (7) Human PTH (1-34)-Met 18 [O] 0.13 0.09 0.16 0.06 0.07 0.21 0.23 0.09 (8) Human PTH (1-34)-Trp 23 [dioxidation] ND ND ND ND ND ND ND ND (9) Mixture containing human PTH (1-34)- ND ND ND ND ND ND ND ND Trp 23 [monoxidation] and human PTH (1-34)-Trp 23 [dioxidation-formic acid elimination] Ex.: Example; CEx.: Comparative Example
(153) TABLE-US-00009 TABLE 7 Total amount of analogs (total amount) and amount of each analog (%) Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5 CEx. 1 CEx.2 Total amount (%) 0.88 0.76 1.51 0.95 0.72 6.27 3.09 (1) Human PTH (1-34)-Met 8 [O]-Met 18 0.03 ND ND ND ND 0.10 0.05 [O]-Trp 23 [dioxidation] (2) Human PTH (1-34)-Met 8 [O]-Met 18 0.02 ND ND ND ND 0.07 ND [O]-Trp 23 [dioxidation-formic acid elimination] (3) Mixture containing human PTH (1-34)- 0.03 ND ND 0.03 0.03 0.29 0.12 Met 8 [O]-Met 18 [O] and human PTH (1-34)-Met 8 [O]- Trp 23 [dioxidation] (4) Human PTH (1-34)-Met 18 [O]- Trp 23 0.06 0.02 0.03 0.05 ND 0.69 0.27 [dioxidation] (5) Human PTH (1-34)-Met 18 [O]- Trp 23 ND ND 0.03 ND ND 0.19 ND [dioxidation-formic acid elimination] (6) Human PTH (1-34)-Met 8 [O] 0.14 0.09 0.24 0.15 0.09 0.93 0.34 (7) Human PTH (1-34)-Met 18 [O] 0.19 0.15 0.36 0.25 0.10 1.42 1.08 (8) Human PTH (1-34)-Trp 23 [dioxidation] 0.09 0.04 0.10 0.11 0.04 0.74 0.69 (9) Mixture containing human PTH (1-34)- 0.05 ND 0.09 0.04 0.02 0.40 0.08 Trp 23 [monoxidation] and human PTH (1-34)-Trp 23 [dioxidation-formic acid elimination] Ex.: Example; CEx.: Comparative Example
Test Example 2
(154) Human PTH (1-34) analogs were produced and fractionated, and the fractions were analyzed to estimate the structures of each analog obtained in Test Example 1.
(155) (1) Production and Fractionation of Each Analog
(156) A quantity of 4.00 g of sucrose and 0.20 g of sodium chloride were weighed out and dissolved by adding water for injection to make a placebo solution. Human PTH (1-34) was weighed out exactly and dissolved by adding 100 mL of placebo solution to make a reaction stock solution. An environment having an ozone concentration of approximately 0.08 ppm by ozone concentration meter was produced using an ozone generator and a blower (initial wind speed approximately 7.2 m/s) to circulate the ozone and make the concentration uniform in a tray having a 40 cm long90 cm wide100 cm high glass door. Approximately 15 mL of the reaction stock solution was dispensed into each 20 mL vial. A stirrer was introduced into the vial, and degradation was carried out while stirring by stirrer until the purity was approximately 20% (in other words, the total amount of human PTH (1-34) analogs was 80%) by exposure (for about 20 hours) to an ozone atmosphere of approximately 0.08 ppm. Furthermore, the purity was confirmed in accordance with the test conditions of Test Example 1. The degraded solution was freeze dried, and a solution dissolved by a suitable amount of water for injection was taken as a forced-degradation solution. The analogs were fractionated under the following conditions using this solution.
(157) <Test Conditions>
(158) The test conditions other than the following were the same as the test conditions in Test Example 1.
(159) <Conditions Different from Test Example 1>
(160) Column: Stainless steel tube 250 mm long having an inner diameter of 9.4 mm packed with 5 m of octadecylsilylated silica gel
(161) Flow rate: 6.0 mL/min
(162) Furthermore, no major differences in the chromatogram pattern were observed despite the fact that the above conditions differed from those of Test Example 1.
(163) Nine analogs were fractionated under the above chromatography conditions. They were desalted and concentrated, and the freeze-dried products were dissolved in distilled water to obtain each analog (undigested compound). Each analog (undigested compound) and the forced-degradation solution were analyzed by HPLC under the test conditions of Test Example 1, and the relative retention time of each analog (undigested compound) was calculated, taking the retention time of human PTH (1-34) in the forced-degradation solution as 1.
(164) <Results>
(165) Basically complete agreement with the relative retention time of each analog in the forced-degradation solution was confirmed. Table 8 shows the results on the relative retention times.
(166) TABLE-US-00010 TABLE 8 Comparison of the relative retention time of the relevant peaks of analogs (undigested compounds) and forced-degradation solution Analog (undigested Forced-degradation compound) solution Human PTH (1-34) 1.00 Analog (1) 0.43 0.42 Analog (2) 0.44 0.43 Analog (3) 0.46 0.46 Analog (4) 0.49 0.49 Analog (5) 0.51 0.51 Analog (6) 0.55 0.55 Analog (7) 0.62 0.62 Analog (8) 0.65 0.65 Analog (9) 0.70 0.70
(167) (2) Structural Estimation Analysis of Each Analog
(168) Each of the above analogs (undigested compounds) and human PTH (1-34) standard were digested by trypsin to produce analogs (digested compounds) and standard solution (digested compound). Ten of these samples were analyzed by LC/MS/MS under the following conditions.
(169) <LC/MS/MS Conditions>
(170) Detector: Ultraviolet absorptiometer (measurement wavelength: 210 nm)
(171) Column: Stainless steel tube 150 mm long having an inner diameter of 1.5 mm packed with 5 m of octadecylsilylated silica gel
(172) Column temperature: Constant temperature near 40 C.
(173) Mobile phase: Mobile phase A: Mixed aqueous solution containing trifluoroacetic acid (1:1000)
(174) Mobile phase B: Acetonitrile
(175) Mobile phase feed: Concentration gradient control is provided by varying the mixture ratio of mobile phase A and mobile phase B as follows.
(176) Time after Injection:
(177) TABLE-US-00011 TABLE 9 Concentration gradient control Time after sample injection (min) Mobile phase A (vol %) Mobile phase B (vol %) 0-30 95.fwdarw.55 5.fwdarw.45 30-40 55 45
(178) Flow rate: 0.1 mL/min
(179) Sample temperature: Constant temperature near 5 C.
(180) Detection time: 45 minutes after injection of the sample solution. However, this is from the back of the solvent peak
(181) Ionization mode: ES+
(182) Each analog (undigested compound) was analyzed by LC/MS under the following conditions.
(183) <LC/MS Test Conditions>
(184) Conditions other than the following were the same as the LC/MS/MS conditions.
(185) Mobile phase feed: Concentration gradient control is provided by varying the mixture ratio of mobile phase A and mobile phase B as follows.
(186) Time after injection:
(187) TABLE-US-00012 TABLE 10 Concentration gradient control Time after sample injection (min) Mobile phase A (vol %) Mobile phase B (vol %) 0-30 85.fwdarw.55 15.fwdarw.45 30-40 55 45
(188) <Results>
(189) The results of structural analysis of the nine analogs in Test Example 2 were as follows.
(190) <Human PTH (1-34)>
(191) Table 11 shows the expected fragments of human PTH (1-34) produced by trypsin digestion.
(192) TABLE-US-00013 TABLE 11 Expected fragments of human PTH (1-34) Fragment Estimated No. structure Amino acid sequence T1 PTH (1-13) Ser-Val-Ser-Glu-Ile-Gln-Leu-Met- His-Asn-Leu-Gly-Lys SEQ ID NO: 1 T2 PTH (14-20) His-Leu-Asn-Ser-Met-Glu-Arg SEQ ID NO: 2 T3 PTH (21-25) Val-Glu-Trp-Leu-Arg SEQ ID NO: 3 T4 PTH (26).sup. Lys T5 PTH (27).sup. Lys T6 PTH (28-34) Leu-Gln-Asp-Val-His-Asn-Phe SEQ ID NO: 5
(193) Table 12 shows the results of measurement of the mass of each fragment confirmed in LC/MS/MS of the standard solution (digested compound). The measured values of each fragment in the standard solution (digested compound) were compared with the calculated mass, and it was confirmed that five fragments of estimated structure were obtained in human PTH (1-34).
(194) TABLE-US-00014 TABLE 12 Results of mass measurement of standard solution (digested compound) Retention Measured mass Calculated mass Estimated Fragment time Mass (mono.) Mass (mono.) structure No. 13.423 885.4984 885.4127 PTH (14-20) T2 18.371 871.5030 871.4188 PTH (28-34) T6 18.371 999.6100 999.5138 PTH (27-34) T5-6 21.222 701.4508 701.3861 PTH (21-25) T3 22.618 1454.8715 1454.7551 PTH (1-13) T1
(195) <Analog 1>
(196) The analog showing a retention time=0.43 in the column Analogs (undigested compounds) in Table 8 was taken as analog 1, and Table 13 shows the results of mass measurement in LC/MS/MS of analog 1 (digested compound). Changes in mass of +16 Da in T2, +4 Da in T3, and +16 Da in T1 were confirmed in analog 1 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(197) TABLE-US-00015 TABLE 13 Results of mass measurement of analog 1 (digested compound) Retention Difference time Analog 1 Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 9.578 901.4622 T2 885.4984 +16 Da 18.409 871.4731 T6 871.5030 0 18.409 999.5720 T5-6 999.6100 0 19.096 705.4228 T3 701.4508 +4 Da 19.323 1470.8297 T1 1454.8715 +16 Da
(198) Table 14 shows the results obtained by MS/MS analysis of fragments confirmed to have changes in mass. As a result of comparison with the standard solution (digested compound), changes in mass of +16 Da in Met 18 in T2, +4 Da in Trp 23 in T3, and +16 Da in Met 8 in T1 were confirmed.
(199) TABLE-US-00016 TABLE 14 Results of MS/MS analysis of analog 1 (digested compound) Mass observed on MS/MS spectrum Frag- Analog Standard Amino acid ment 1 solution Estimated with change No. (mono.) (mono.) structure in mass T2 304.1896 304.1960 PTH (19-20) Met 18 +16 Da 434.2278 PTH (18-20) +16 Da 418.2120 PTH (18-20) T3 271.2070 271.2085 PTH (24-25) Trp 23 +4 Da 478.2979 PTH (23-25) +4 Da 474.3203 PTH (23-25) T1 568.3508 568.3636 PTH (9-13) Met 8 +16 Da 715.3823 PTH (8-13) +16 Da 699.4180 PTH (8-13)
(200) Table 15 shows the results obtained by comparing the mass of analog 1 (undigested compound) obtained by LC/MS with the calculated value of 4115.1309 of human PTH (1-34). In analog 1 (undigested compound) peaks of +64 Da and +36 Da were confirmed in comparison to the calculated mass, and the +64 Da peak appeared to be the main peak based on the size of the peaks, as shown in
(201) TABLE-US-00017 TABLE 15 Results of mass measurement of analog 1 (undigested compound) Retention Difference time Measured mass Calculated mass in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 19.749 4179.3280 4115.1309 +64 Da 20.130 4151.3674 4115.1309 +36 Da
(202) Based on the results of MS/MS analysis, it was estimated that human PTH (1-34)+36 Da=(Met 18+16 Da)+(Trp 23+4 Da)+(Met 8+16 Da). The structure of the +4 Da changed form in Trp is b) in
(203) <Analog 2>
(204) The analog showing a retention time=0.44 in the column Analogs (undigested compounds) in Table 8 was taken as analog 2, and Table 16 shows the results of mass measurement in LC/MS/MS of analog 2 (digested compound). Changes in mass of +16 Da in T2, +4 Da in T3, and +16 Da in T1 were confirmed in analog 2 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(205) TABLE-US-00018 TABLE 16 Results of mass measurement of analog 2 (digested compound) Retention Difference time Analog 2 Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 9.58 901.4695 T2 885.4984 +16 Da 18.348 871.4788 T6 871.5030 0 18.348 999.5874 T5-6 999.6100 0 19.059 705.4333 T3 701.4508 +4 Da 19.222 1470.8492 T1 1454.8715 +16 Da
(206) Changes in mass of +16 Da in Met 18 in T2, +4 Da in Trp 23 in T3, and +16 Da in Met 8 in T1 were confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 17 shows the results of comparing the mass of analog 2 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In analog 2 (undigested compound), peaks of +24 Da and +92 Da were confirmed in comparison to the calculated masses, but the reliability of these confirmed masses appeared to be low since basically no peak shape was formed, as shown in
(207) TABLE-US-00019 TABLE 17 Results of mass measurement of analog 2 (undigested compound) Retention Difference time Measured mass Calculated mass in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 20.092 4139.2866 4115.1309 +24 Da 20.632 4207.3668 4115.1309 +92 Da
(208) Based on the results of MS/MS analysis, analog 2 was estimated to have undergone at least changes in mass of human PTH (1-34)+36 Da=(Met 18+16 Da)+(Trp 23+4 Da)+(Met 8+16 Da). In other words, analog 2 was estimated to be human PTH (1-34)-Met 8 [O]-Met 18 [O]-Trp 23 [dioxidation-formic acid elimination].
(209) <Analogs 3 and 4>
(210) The peak showing a retention time=0.46 in the column Analogs (undigested compounds) in Table 8 was derived from a mixture of analogs 3 and 4, as explained below. Table 18 shows the results of mass measurement in LC/MS/MS of a mixture of analogs 3 and 4 (digested compound). Changes in mass of +16 Da in T2, +4 Da in T3, and +16 Da in T1 were confirmed in the mixture of analogs 3 and 4 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound). T2 and T3 fragments not associated with changes in mass were also confirmed.
(211) TABLE-US-00020 TABLE 18 Results of mass measurement of a mixture of analogs 3 and 4 (digested compound) Retention Difference time Analog 3 Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 9.813 901.4778 T2 885.4984 +16 Da 13.475 885.4846 T2 885.4984 0 18.326 871.4844 T6 871.5030 0 18.326 999.5800 T5-6 999.6100 0 18.959 705.4266 T3 701.4508 +4 Da 19.223 1470.8373 T1 1454.8715 +16 Da 21.195 701.4322 T3 701.4508 0
(212) Changes in mass of +16 Da in Met 18 in T2, +4 Da in Trp 23 in T3, and +16 Da in Met 8 in T1 were confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 19 shows the results of comparing the mass of a mixture of analogs 3 and 4 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In the mixture of analogs 3 and 4 (undigested compound), peaks of +32 Da, +48 Da, and +20 Da were confirmed in comparison to the calculated masses, and +32 Da and +48 Da in an approximate ratio of 1:1 appeared to be the main peak based on the size of the peaks, as shown in
(213) TABLE-US-00021 TABLE 19 Results of mass measurement of a mixture of analogs 3 and 4 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 21.062 4147.3692 4115.1309 +32 Da 21.539 4163.3747 4115.1309 +48 Da 21.843 4135.3897 4115.1309 +20 Da
(214) On the LC/MS/MS chromatogram of a mixture of analogs 3 and 4 (digested compound), T2+16 Da: T2 and T3+4 Da: T3 were each present in an approximately 1:1 ratio, and T2+16 Da: T3+4 Da: T1+16 Da were present in an approximately 1:1:2 ratio. Based on the results of MS/MS analysis, it was estimated that human PTH (1-34)+32 Da=(Met 18+16 Da)+(Met 8+16 Da) and human PTH (1-34)+20 Da=(Trp 23+4 Da)+(Met 8+16 Da). With regard to the latter, Trp 23 was assumed to have undergone a change of a) to b) in the course of trypsin digestion and other such procedures, in the same way as analog 1, and it was estimated that human PTH (1-34)+48 Da=(Trp 23+32 Da)+(Met 8+16 Da). Analogs 3 and 4 were estimated to be human PTH (1-34)+32 Da and human PTH (1-34)+48 Da, respectively. In other words, the peak having a relative retention time=0.46 in Table 8 was estimated to be a peak of a mixture containing human PTH (1-34)-Met 8 [O]-Met 18 [O] and human PTH (1-34)-Met 8 [O]-Trp 23 [dioxidation].
(215) <Analog 5>
(216) The analog showing a retention time=0.49 in the column Analogs (undigested compounds) in Table 8 was taken as analog 5, and Table 20 shows the results of mass measurement in LC/MS/MS of analog 5 (digested compound). Changes in mass of +16 Da in T2 and +4 Da in T3 were confirmed in analog 5 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(217) TABLE-US-00022 TABLE 20 Results of mass measurement of analog 5 (digested compound) Retention Difference time Analog 4 [sic] Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 9.587 901.4664 T2 885.4984 +16 Da 18.321 871.4904 T6 871.5030 0 18.321 999.5957 T5-6 999.6100 0 19.012 705.4388 T3 701.4508 +4 Da 22.561 1454.8492 T1 1454.8715 0
(218) Changes in mass of +16 Da in Met 18 in T2 and +4 Da in Trp 23 in T3 were confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 21 shows the results of comparing the mass of analog 5 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In analog 5 (undigested compound), peaks of +48 Da and +20 Da were confirmed in comparison to the calculated masses, and +48 Da appeared to be the main peak based on the size of the peaks, as shown in
(219) TABLE-US-00023 TABLE 21 Results of mass measurement of analog 5 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 22.081 4163.3763 4115.1309 +48 Da 22.514 4135.3902 4115.1309 +20 Da
(220) Based on the results of MS/MS analysis, it was estimated that human PTH (1-34)+20 Da=(Met 18+16 Da)+(Trp 23+4 Da). Trp 23 was assumed to have undergone a change of a) to b) in the course of trypsin digestion and other such procedures, in the same way as analog 1. The main peak of analog 5 (undigested compound) was estimated to be human PTH (1-34)+48 Da=(Met 18+16 Da)+(Trp 23+32 Da). In other words, analog 5 was estimated to be human PTH (1-34)-Met 18 [O]-Trp 23 [dioxidation].
(221) <Analog 6>
(222) The analog showing a retention time=0.51 in the column Analogs (undigested compounds) in Table 8 was taken as analog 6, and Table 22 shows the results of mass measurement in LC/MS/MS of analog 6 (digested compound). Changes in mass of +16 Da in T2 and +4 Da in T3 were confirmed in analog 6 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound). T1 fragments in which there was no change in mass were also confirmed.
(223) TABLE-US-00024 TABLE 22 Results of mass measurement of analog 6 (digested compound) Retention Difference time Analog 5 [sic] Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 9.589 901.4699 T2 885.4984 +16 Da 18.332 871.4912 T6 871.5030 0 18.332 999.5869 T5-6 999.6100 0 19.032 705.4321 T3 701.4508 +4 Da 22.583 1454.8536 T1 1454.8715 0
(224) Changes in mass of +16 Da in Met 18 in T2 and +4 Da in Trp 23 in T3 were confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 23 shows the results of comparing the mass of analog 6 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In analog 6 (undigested compound), a peak of +20 Da was confirmed in comparison with the calculated mass.
(225) TABLE-US-00025 TABLE 23 Results of mass measurement of analog 6 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 22.580 4135.6585 4115.1309 +21 Da (+20 Da)
(226) Based on the results of MS/MS analysis, analog 6 was estimated to be human PTH (1-34)+20 Da=(Met 18+16 Da)+(Trp 23+4 Da). In other words, analog 6 was estimated to be human PTH (1-34)-Met 18 [O]-Trp 23 [dioxidation-formic acid elimination].
(227) <Analog 7>
(228) The analog showing a retention time=0.55 in the column Analogs (undigested compounds) in Table 8 was taken as analog 7, and Table 24 shows the results of mass measurement in LC/MS/MS of analog 7 (digested compound). A change in mass of +16 Da in T1 was confirmed in analog 7 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(229) TABLE-US-00026 TABLE 24 Results of mass measurement of analog 7 (digested compound) Retention Difference time Analog 6 [sic] Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 13.405 855.4859 T2 885.4984 0 18.374 871.4885 T6 871.5030 0 18.374 999.5920 T5-6 999.6100 0 19.296 1470.8591 T1 1454.8715 +16 Da 21.225 701.4354 T3 701.4508 0
(230) A change in mass of +16 Da in Met 8 in T1 was confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 25 shows the results of comparing the mass of analog 7 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In analog 7 (undigested compound), a peak of +16 Da was confirmed in comparison with the calculated mass.
(231) TABLE-US-00027 TABLE 25 Results of mass measurement of analog 7 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 22.353 4131.7101 4115.1309 +17 Da (+16 Da)
(232) Based on the results of MS/MS analysis, analog 7 was estimated to be human PTH (1-34)+16 Da=(Met 8+16 Da). In other words, analog 7 was estimated to be human PTH (1-34)-Met 8 [0].
(233) <Analog 8>
(234) The analog showing a retention time=0.62 in the column Analogs (undigested compounds) in Table 8 was taken as analog 8, and Table 26 shows the results of mass measurement in LC/MS/MS of analog 8 (digested compound). A change in mass of +16 Da in T2 was confirmed in analog 8 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(235) TABLE-US-00028 TABLE 26 Results of mass measurement of analog 8 (digested compound) Retention Difference time Analog 7 [sic] Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 9.709 901.4782 T2 885.4984 +16 Da 18.356 871.4903 T6 871.5030 0 18.356 999.5916 T5-6 999.6100 0 21.228 701.4383 T3 701.4508 0 22.636 1454.8592 T1 1454.8715 0
(236) A change in mass of +16 Da in Met 18 in T2 was confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 27 shows the results of comparing the mass of analog 8 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In analog 8 (undigested compound), a peak of +16 Da was confirmed in comparison with the calculated mass, as shown in
(237) TABLE-US-00029 TABLE 27 Results of mass measurement of analog 8 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 23.129 4131.7286 4115.1309 +17 Da (+16 Da)
(238) Based on the results of MS/MS analysis, analog 8 was estimated to be human PTH (1-34)+16 Da=(Met 18+16 Da). In other words, analog 8 was estimated to be human PTH (1-34)-Met 18 [0].
(239) <Analog 9>
(240) The analog showing a retention time=0.65 in the column Analogs (undigested compounds) in Table 8 was taken as analog 9, and Table 28 shows the results of mass measurement in LC/MS/MS of analog 9 (digested compound). A change in mass of +4 Da in T3 was confirmed in analog 9 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(241) TABLE-US-00030 TABLE 28 Results of mass measurement of analog 9 (digested compound) Retention Difference time Analog 8[sic] Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 13.392 885.4876 T2 885.4984 0 18.329 871.4896 T6 871.5030 0 18.329 999.5977 T5-6 999.6100 0 19.023 705.4405 T3 701.4508 +4 Da 22.567 1454.8638 T1 1454.8715 0
(242) A change in mass of +4 Da in Trp 23 in T3 was confirmed, in the same way as in analog 1, as a result of MS/MS analysis of fragments confirmed to have changes in mass. Table 29 shows the results of comparing the mass of analog 9 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In analog 9 (undigested compound), peaks of +32 Da and +4 Da were confirmed in comparison with the calculated mass, and +32 Da appeared to be the main peak based on the size of the peaks, as shown in
(243) TABLE-US-00031 TABLE 29 Results of mass measurement of analog 9 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 23.729 4147.8250 4115.1309 +33 Da (+32 Da) 24.087 4119.8303 4115.1309 +5 Da (+4 Da)
(244) Based on the results of MS/MS analysis, it was estimated that human PTH (1-34)+4 Da=(Trp 23+4 Da). Trp 23 was assumed to have undergone a change of a) to b) in the course of trypsin digestion and other such procedures, in the same way as analog 1. The main peak of analog 9 (undigested compound) was estimated to be human PTH (1-34)+32 Da=(Trp 23+32 Da). In other words, analog 9 was estimated to be human PTH (1-34)-Trp 23 [dioxidation].
(245) <Analogs 10 and 11>
(246) The peak showing a retention time=0.70 in the column Analogs (undigested compounds) in Table 8 was derived from a mixture of analogs 10 and 11, as explained below. Table 30 shows the results of mass measurement in LC/MS/MS of a mixture of analogs 10 and 11 (digested compound). Changes in mass of +16 Da and +4 Da in T3 were confirmed as separate fragments in the mixture of analogs 10 and 11 (digested compound) by comparison with the measured values of the relevant fragments in the standard solution (digested compound).
(247) TABLE-US-00032 TABLE 30 Results of mass measurement of a mixture of analogs 10 and 11 (digested compound) Retention Difference time Analog 9 [sic] Standard solution in mass (min) Mass (mono.) Frag. No. Mass (mono.) (F = 0, 4/5) 13.449 885.4893 T2 885.4984 0 18.337 871.4925 T6 871.5030 0 18.337 999.5985 T5-6 999.6100 0 18.821 717.4391 T3 701.4508 +16 Da 19.032 705.4407 T3 701.4508 +4 Da 22.563 1454.8634 T1 1454.8715 0
(248) Table 31 shows the results obtained by MS/MS analysis of fragments confirmed to have changes in mass. A change in mass of +16 Da in Trp 23 in one T3 was confirmed as a result of comparison with the standard solution (digested compound). The structure of the changed form of +16 Da in Trp was expected to be c) in
(249) TABLE-US-00033 TABLE 31 Results of MS/MS analysis of a mixture of analogs 10 and 11 (digested compound) Mass observed on MS/MS spectrum Analog Standard Amino Fragment 9 [sic] solution acid with No. (mono.) (mono.) Estimated structure change in mass T3 271.2131 271.2085 PTH (24-25) Trp 23 +16 Da 490.3079 PTH (23-25) +16 Da 474.3203 PTH (23-25)
(250) Table 32 shows the results of comparing the mass of a mixture of analogs 10 and 11 (undigested compound) obtained by LC/MS with the calculated mass of 4115.1309 of human PTH (1-34). In the mixture of analogs 10 and 11 (undigested compound), peaks of +16 Da and +4 Da were observed comparison to the calculated masses, as shown in
(251) TABLE-US-00034 TABLE 32 Results of mass measurement of a mixture of analogs 10 and 11 (undigested compound) Retention time Measured mass Calculated mass Difference in mass (min) Mass (mono.) Mass (mono.) (F = 0, 4/5) 22.956 4131.7912 4115.1309 +17 Da (+16 Da) 24.151 4119.8118 4115.1309 +5 Da (+4 Da)
(252) Based on the results of MS/MS analysis, these were attributed as human PTH (1-34)+16 Da=(Trp 23+16 Da) and human PTH (1-34)+4 Da=(Trp 23+4 Da), and the peak showing a retention time=0.70 in the column Analogs (undigested compounds) in Table 8 was estimated to be a mixture of analogs 10 and 11. In other words, analog 10 was estimated to be human PTH (1-34)-Trp 23 [monoxidation], and analog 11 was estimated to be human PTH (1-34)-Trp 23 [dioxidation-formic acid elimination].
(253) <Summary of Structural Analysis>
(254) Table 33 shows the relative retention time and estimated structure results of each analog.
(255) TABLE-US-00035 TABLE 33 Relative retention time and estimated structure of each analog Relative Amino Summary of change retention acid Change Nature of No. time changed in mass change Name of analog (1) 0.42 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 [O]-Met 18 Met 18 16 Da Oxidation [O]-Trp 23 [dioxidation] Trp 23 32 Da a) (2) 0.43 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 [O]-Met 18 Met 18 16 Da Oxidation [O]-Trp 23 [dioxidation-formic acid Trp 23 4 Da b) elimination] (3) 0.46 Met 8 16 Da Oxidation Mixture containing human PTH (1-34)- Met 18 16 Da Oxidation Met 8 [O]-Met 18 [O] and 0.46 Met 8 16 Da Oxidation human PTH (1-34)-Met 8 [O]-Trp 23 Trp 23 32 Da a) [dioxidation] (4) 0.49 Met 18 16 Da Oxidation Human PTH (1-34)-Met 18 [O]-Trp 23 Trp 23 32 Da a) [dioxidation] (5) 0.51 Met 18 16 Da Oxidation Human PTH (1-34)-Met 18 [O]-Trp 23 Trp 23 4 Da b) [dioxidation-formic acid elimination] (6) 0.55 Met 8 16 Da Oxidation Human PTH (1-34)-Met 8 [O] (7) 0.62 Met 18 16 Da Oxidation Human PTH (1-34)-Met 18 [O] (8) 0.65 Trp 23 32 Da a) Human PTH (1-34)-Trp 23 [dioxidation] (9) 0.7 Trp 23 16 Da c) Mixture containing human PTH (1-34)- 0.7 Trp 23 4 Da b) Trp 23 [monoxidation] and human PTH (1-34)-Trp 23 [dioxidation-formic acid elimination]
INDUSTRIAL APPLICABILITY
(256) Since a freeze-dried preparation containing high-purity PTH peptide is provided by the present invention, the present invention can be used in the pharmaceutical manufacturing industry.
EXPLANATION OF SYMBOLS
(257) 1: Large door 2: Small door 3: Sub-door (open) 4: Sub-door (closed) 5: Airflow-adjusting cover